San Diego, CA, United States
San Diego, CA, United States

Time filter

Source Type

News Article | May 9, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $350 million aggregate principal amount of 0.75% Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The size of the offering was increased by $50 million from the previously announced offering size of $300 million. DexCom also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50 million aggregate principal amount of notes solely to cover over-allotments, if any. The sale of the notes is expected to close on May 12, 2017, subject to customary closing conditions, and is expected to result in approximately $340.4 million in net proceeds to DexCom after deducting fees and commissions and estimated offering expenses payable by DexCom (assuming no exercise of the initial purchasers’ over-allotment option). The notes will be senior, unsecured obligations of DexCom, and will bear interest at a rate of 0.75% per year, payable semi-annually in arrears. The notes will mature on May 15, 2022, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding February 15, 2022, the notes will be convertible at the option of holders only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until 5:00 p.m., New York City time, on the business day immediately preceding the maturity date. Upon conversion, the notes may be settled in shares of DexCom’s common stock, cash or a combination of cash and shares of common stock, at the election of DexCom. The initial conversion rate is 10.0918 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $99.09 per share of DexCom’s common stock, representing an approximate 35% premium based on the last reported sale price of Dexcom’s common stock on The NASDAQ Global Select Market on May 8, 2017 of $73.40 per share). The conversion rate and the corresponding conversion price will be subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. Prior to May 15, 2020, the notes will not be redeemable. On or after May 15, 2020, DexCom may redeem for cash all or part of the notes, at its option, if the last reported sale price of DexCom’s common stock has been at least 140% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which DexCom provides notice of redemption. Holders of the notes will have the right to require DexCom to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). DexCom will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following the delivery by DexCom of a notice of redemption. DexCom expects to use the net proceeds of the offering of the notes to repay $75 million of borrowings under its existing credit facility and the remainder for general corporate purposes and capital expenditures, including working capital needs and buildout of its manufacturing facility in Arizona. DexCom may also use the net proceeds to expand its current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, DexCom does not have any commitments with respect to any such acquisitions or investments at this time. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of DexCom’s common stock, if any, into which the notes are convertible) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes will be made only by means of a private offering memorandum. The offering is being made to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and any shares of DexCom’s common stock issuable upon conversion of the notes have not been and are not expected to be registered under the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties, including, without limitation, statements regarding the timing and closing of DexCom’s offering of the notes and expected use of net proceeds of the offering. Statements containing words such as “could,” “believe,” “expect,” “intend,” “will,” or similar expressions constitute forward-looking statements. Factors that may contribute to such differences include, but are not limited to, risks related to whether DexCom will close the offering of the notes on the expected date, or at all, prevailing market and other general economic conditions, whether DexCom will be able to satisfy the conditions required to close any sale of the notes, and the fact that DexCom’s management will have broad discretion in the use of the proceeds from any sale of the notes. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect DexCom’s business and financial results, please review the “Risk Factors” described in DexCom’s Annual Report on Form 10-K for the year ended December 31, 2016 and DexCom’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the Securities and Exchange Commission, or SEC, and in DexCom’s other filings with the SEC. Except as may be required by law, DexCom does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.


On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 549,433 shares. The stock ended the session 0.37% higher at $2.72. The Company's shares are trading 7.62% below their 50-day moving average. Moreover, shares of Organovo, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 42.98. On May 01st, 2017, Organovo announced a collaboration with the University of Virginia (UVA) to develop 3D bioprinted tissues for volumetric muscle loss injury. The research will take place in the laboratory of George J. Christ, Ph.D., professor of biomedical engineering and orthopaedic surgery at UVA. The free research report on ONVO is available at: San Diego, California headquartered DexCom Inc.'s stock closed the day 3.69% lower at $73.40. A total volume of 2.17 million shares was traded, which was above their three months average volume of 937,590 shares. The Company's shares have advanced 22.95% since the start of this year. The stock is trading 6.56% below its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 41.31. On May 03rd, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $90 a share. On May 04th, 2017, DexCom announced that its G5 Mobile CGM System can now be used with Apple Watches throughout Europe by downloading the latest version of the G5 Mobile App - iOS 1.6. By adding Apple Watch as another display device, Europeans living with diabetes have even more options to view their glucose readings and alerts on Dexcom's G5 Mobile CGM System to help better manage their diabetes. The complimentary report on DXCM can be downloaded at: Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 703,163 shares. The stock ended yesterday's trading session 0.09% higher at $107.19. The Company's shares have advanced 9.53% in the past month, 16.06% in the previous three months, and 17.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.40% and 19.47%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 78.18. On April 26th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $110 a share to $115 a share. On May 01st, 2017, Quest Diagnostics announced that its senior Vice President and Chief Information Officer, Lidia L. Fonseca, has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24th, 2017, recognizes CIOs of multibillion-dollar companies who have demonstrated the ability to generate value through innovation. Visit us today and download our complete research report on DGX for free at: Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock finished Monday's session 0.13% lower at $142.19 with a total trading volume of 499,035 shares. The Company's shares have advanced 9.49% over the previous three months and 10.76% since the start of this year. The stock is trading above its 200-day moving average by 4.81%. Additionally, shares of Laboratory Corp., which operates as an independent clinical laboratory company worldwide, have an RSI of 50.73. On May 04th, 2017, LabCorp® has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services and Catholic Health Initiatives. With the acquisition, LabCorp assumes PAML's ownership interests in several joint ventures: Colorado Laboratory Services, Kentucky Laboratory Services, MountainStar Clinical Laboratories, PACLAB Network Laboratories, and Tri-Cities Laboratory.  Get free access to your technical report on LH at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | May 15, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and finally “Events and Webcasts” and will be archived there for future reference. DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.


News Article | May 8, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $300 million aggregate principal amount of Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate principal amount of notes solely to cover over-allotments, if any. The notes will be senior, unsecured obligations of DexCom, and interest will be payable semi-annually in arrears. The notes will mature on May 15, 2022, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding February 15, 2022, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until 5:00 p.m., New York City time, on the business day immediately preceding the maturity date. Upon conversion, the notes may be settled in shares of DexCom’s common stock, cash or a combination of cash and shares of the common stock, at the election of DexCom. Prior to May 15, 2020, the notes will not be redeemable. On or after May 15, 2020, DexCom may redeem for cash all or part of the notes, at its option, if the last reported sale price of DexCom’s common stock has been at least 140% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which DexCom provides notice of redemption. Holders of the notes will have the right to require DexCom to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). DexCom will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by us of a notice of redemption. The interest rate, conversion rate, offering price and other terms are to be determined upon pricing of the notes. DexCom expects to use the net proceeds of the offering of the notes to repay $75 million of borrowings under its existing credit facility and the remainder for general corporate purposes and capital expenditures, including working capital needs and buildout of its manufacturing facility in Arizona. DexCom may also use the net proceeds to expand its current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, DexCom does not have any commitments with respect to any such acquisitions or investments at this time. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of DexCom’s common stock, if any, into which the notes are convertible) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes will be made only by means of a private offering memorandum. The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and any shares of DexCom’s common stock issuable upon conversion of the notes have not been and are not expected to be registered under the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties, including, without limitation, statements regarding DexCom’s proposed offering of the notes and expected use of net proceeds of the offering. Statements containing words such as “could,” “believe,” “expect,” “intend,” “will,” or similar expressions constitute forward-looking statements. Factors that may contribute to such differences include, but are not limited to, risks related to whether DexCom will consummate the offering of the notes on the expected terms, or at all, the anticipated principal amount of the notes, prevailing market and other general economic conditions, whether DexCom will be able to satisfy the conditions required to close any sale of the notes, and the fact that DexCom’s management will have broad discretion in the use of the proceeds from any sale of the notes. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect DexCom’s business and financial results, please review the “Risk Factors” described in DexCom’s Annual Report on Form 10-K for the year ended December 31, 2016 and DexCom’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the Securities and Exchange Commission, or SEC, and in DexCom’s other filings with the SEC. Except as may be required by law, DexCom does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.


Global Mobile Healthcare (mHealth) Market by Monitoring Devices, Growth Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 Maryland Heights, MO, April 21, 2017 --( Browse Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/ The global mobile healthcare (mHealth) market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on device types (blood pressure, blood glucose, cardiac rhythm, pulse, sleep apnea, and multi-parameter monitors) and forecasts growth trends (CAGR% - 2017 to 2021). The global mobile healthcare (mHealth) market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global mobile healthcare (mHealth) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global mobile healthcare (mHealth) market and included in this report are AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dräger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare. 1. Monitoring Device 1.1. Blood Pressure Monitors 1.2. Cardiac Monitors 1.3. Glucose Monitors 1.4. Multi-parameter Monitors 1.5. Pulse Oximeters 1.6. Sleep Apnea Monitors 1.7. Others 2. Geography (Region, Country) 2.1. North America (U.S., Canada) 2.2. Latin America (Brazil, Mexico, Rest of LA) 2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4. Asia Pacific (Japan, China, India, Rest of APAC) 2.5. Rest of the World 3. Company Profiles 3.1. Bayer HealthCare AG 3.2. BioTelemetry, Inc. (CardioNet, Inc.) 3.3. Boston Scientific Corporation 3.4. DexCom, Inc. 3.5. Dräger AG 3.6. F. Hoffmann-La Roche Ltd. 3.7. FitBit, Inc. 3.8. Fora Care Inc. 3.9. iHealth Labs, Inc. 3.10. Johnson & Johnson 3.11. LifeWatch AG 3.12. Masimo Corporation 3.13. Medisana AG 3.14. Medtronic, Inc. 3.15. Nonin Medical, Inc. 3.16. Omron Healthcare, Inc. 3.17. Withings, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 21, 2017 --( PR.com )-- Mobile Health (mHealth) is a sub-segment of eHealth consisting mobile communication devices, such as mobile phones, tablet computers and PDAs, for health services and information exchange. mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery of healthcare information to practitioners, researchers, and patients, real-time monitoring of patient vital signs, and direct provision of care (via mobile telemedicine). Mobile Health (mHealth) is most commonly used for the practice of clinical medicine and public health with the usage of mobile phones and tablets. Increasing incidences of chronic diseases and geriatric population, increase in the number of clinical trial groups, home care agencies and disease management companies are some of the factors that are driving the global mobile healthcare (mHealth) market.Browse Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/The global mobile healthcare (mHealth) market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on device types (blood pressure, blood glucose, cardiac rhythm, pulse, sleep apnea, and multi-parameter monitors) and forecasts growth trends (CAGR% - 2017 to 2021). The global mobile healthcare (mHealth) market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global mobile healthcare (mHealth) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global mobile healthcare (mHealth) market and included in this report are AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dräger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare.1. Monitoring Device1.1. Blood Pressure Monitors1.2. Cardiac Monitors1.3. Glucose Monitors1.4. Multi-parameter Monitors1.5. Pulse Oximeters1.6. Sleep Apnea Monitors1.7. Others2. Geography (Region, Country)2.1. North America (U.S., Canada)2.2. Latin America (Brazil, Mexico, Rest of LA)2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)2.4. Asia Pacific (Japan, China, India, Rest of APAC)2.5. Rest of the World3. Company Profiles3.1. Bayer HealthCare AG3.2. BioTelemetry, Inc. (CardioNet, Inc.)3.3. Boston Scientific Corporation3.4. DexCom, Inc.3.5. Dräger AG3.6. F. Hoffmann-La Roche Ltd.3.7. FitBit, Inc.3.8. Fora Care Inc.3.9. iHealth Labs, Inc.3.10. Johnson & Johnson3.11. LifeWatch AG3.12. Masimo Corporation3.13. Medisana AG3.14. Medtronic, Inc.3.15. Nonin Medical, Inc.3.16. Omron Healthcare, Inc.3.17. Withings, Inc.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


— The “Continuous Glucose Monitoring Systems Market - Medical Devices Pipeline Assessment, 2017” the report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products. Browse the 157 Tables and Figures, 70 Companies, Spread across 268 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=958615. Scope of the Report: Extensive coverage of the Continuous Glucose Monitoring Systems under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: A. Menarini Diagnostics S.r.l., Abbott Diabetes Care, Inc., Advanced Biosensors-Ohio, Llc, Advanced Medical Electronics Corporation, Arkal Medical, Inc., Bio-Impedance General Ltd., Biorasis, Inc., Biovotion AG, CALISTO MEDICAL, INC. (Inactive), Cardiff University Company, City, University of London, Columbia University, ConvaTec Group Plc, Cyber Medical Ltd., Debiotech SA, DexCom Inc, DirectSens GmbH, Echo Therapeutics Inc, Ecole Polytechnique Federale de Lausanne, eLutions Integrated, EyeSense GmbH, Flowsion A/S, Gili Medical Ltd, Globe Medical Tech Inc, and Others. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=958615. Continuous Glucose Monitoring Systems Market- Recent Developments : Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand Mar 29, 2017: ConvaTec Group: Directorate changes Mar 28, 2017: Novo Acquires 19.95% Stake in Convatec from Nordic Capital and Avista for USD1.22 Billion Mar 28, 2017: ConvaTec: Proposed Directorate Changes Mar 27, 2017: Integrity Applications Board Appoints John Graham CEO and Chairman, Angela Strand Vice Chairman Mar 24, 2017: Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million Mar 21, 2017: Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter Mar 13, 2017: DexCom Appoints Richard Collins to Board of Directors Mar 08, 2017: Tandem Diabetes Care Reports 2016 Financial Results Continuous Glucose Monitoring Systems Market- Recent Developments for 2017, January and February is also mentioned. List of Tables Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Segment Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Table 5: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date And more List of Figures Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials Complete Table of Content is Available at Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2017. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/958615-continuous-glucose-monitoring-systems-medical-devices-pipeline-assessment-2017.html


News Article | May 2, 2017
Site: www.prnewswire.co.uk

Ventricular Assist Devices - our new study reveals trends, R&D progress, and predicted revenues Where is the VAD market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 154-page report provides 104 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing VAD market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 3 Product Types and 3 Applications. In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 12 leading national markets: • North America: • The US • Mexico • Canada The report also includes profiles and forecasts for some of the leading companies in the Ventricular Assist Device market, with a focus on the VAD segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for VAD will surpass $900m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of heart disease, and increasing ageing population will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the VAD Market report helps you In summary, our 154-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Ventricular Assist Devices market and 2 different segmentations, with 3 product categories and 3 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 6 regional markets and 12 of the leading national markets - US, Mexico, Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Russia, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the Ventricular Assist device market and leading companies. You find data, trends and predictions. Get our report today Ventricular Assist Device (VAD) Market Forecast 2017-2027: Revenue Prospects by Product Type (LAVD, RVAD, BiVAD), Application (BTT & BTD Therapy, Destination Therapy, BTR Therapy) and Geography. Avoid missing out - get our report now. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100 Abbottdiabetescare.Com ABIOMED, Inc. Acelity LP, Inc. Advocate Health Care Network Alere, Inc. ALung Technologies Inc. American Heart Association Animas Corporation Asahi Kasei Medical Co. Ltd. Baxter International, Inc. Bodytel Gmbh Boston Scientific Corp. C.R. Bard, Inc. (New Jersey) Cedars-Sinai Cellnovo Group SA Circulite Inc. CryoLife, Inc. DexCom, Inc. Edwards Lifesciences Corp. Exactech, Inc. Guidant Corporation HeartWare International, Inc. Insulet Corp. International Society For Heart And Lung Transplantation Inc Jarvik Heart Inc. LeMaitre Vascular, Inc. Leviticus-Cardio Ltd. LivaNova Plc Mayo Foundation For Medical Education And Research Medtronic Plc Micromed Cardiovascular Inc. Nipro Corp. NuVasive, Inc. On-X Life Technologies Inc. Option Care Enterprises Inc. Organ Recovery Systems Inc. Peter Brasseler Holdings Llc Presence Prv Health Smith & Nephew Plc St. Jude Medical, Inc. Sunshine Heart, Inc. Teleflex, Inc. Terumo Corp. Terumo Heart Incorporated Thoratec Corporation United Network For Organ Sharing Valtech Cardio Ltd Visualase Inc. Walgreens Infusion Services Inc. World Heart Corporation Zimmer Biomet Holdings, Inc. List of Organizations Advocate Health Care Network American Heart Association Food and Drug Administration (FDA) Health Canada Mayo Foundation For Medical Education And Research Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) Presence Prv Health United Nations United Network For Organ Sharing World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 2, 2017
Site: www.prnewswire.com

Ventricular Assist Devices - our new study reveals trends, R&D progress, and predicted revenues Where is the VAD market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 154-page report provides 104 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing VAD market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 3 Product Types and 3 Applications. In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 12 leading national markets: • North America: • The US • Mexico • Canada The report also includes profiles and forecasts for some of the leading companies in the Ventricular Assist Device market, with a focus on the VAD segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for VAD will surpass $900m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of heart disease, and increasing ageing population will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the VAD Market report helps you In summary, our 154-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Ventricular Assist Devices market and 2 different segmentations, with 3 product categories and 3 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 6 regional markets and 12 of the leading national markets - US, Mexico, Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Russia, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the Ventricular Assist device market and leading companies. You find data, trends and predictions. Get our report today Ventricular Assist Device (VAD) Market Forecast 2017-2027: Revenue Prospects by Product Type (LAVD, RVAD, BiVAD), Application (BTT & BTD Therapy, Destination Therapy, BTR Therapy) and Geography. Avoid missing out - get our report now. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100 Abbottdiabetescare.Com ABIOMED, Inc. Acelity LP, Inc. Advocate Health Care Network Alere, Inc. ALung Technologies Inc. American Heart Association Animas Corporation Asahi Kasei Medical Co. Ltd. Baxter International, Inc. Bodytel Gmbh Boston Scientific Corp. C.R. Bard, Inc. (New Jersey) Cedars-Sinai Cellnovo Group SA Circulite Inc. CryoLife, Inc. DexCom, Inc. Edwards Lifesciences Corp. Exactech, Inc. Guidant Corporation HeartWare International, Inc. Insulet Corp. International Society For Heart And Lung Transplantation Inc Jarvik Heart Inc. LeMaitre Vascular, Inc. Leviticus-Cardio Ltd. LivaNova Plc Mayo Foundation For Medical Education And Research Medtronic Plc Micromed Cardiovascular Inc. Nipro Corp. NuVasive, Inc. On-X Life Technologies Inc. Option Care Enterprises Inc. Organ Recovery Systems Inc. Peter Brasseler Holdings Llc Presence Prv Health Smith & Nephew Plc St. Jude Medical, Inc. Sunshine Heart, Inc. Teleflex, Inc. Terumo Corp. Terumo Heart Incorporated Thoratec Corporation United Network For Organ Sharing Valtech Cardio Ltd Visualase Inc. Walgreens Infusion Services Inc. World Heart Corporation Zimmer Biomet Holdings, Inc. List of Organizations Advocate Health Care Network American Heart Association Food and Drug Administration (FDA) Health Canada Mayo Foundation For Medical Education And Research Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) Presence Prv Health United Nations United Network For Organ Sharing World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

Loading DexCom Inc. collaborators
Loading DexCom Inc. collaborators